GoodRx (NASDAQ:GDRX) Given New $6.00 Price Target at KeyCorp

GoodRx (NASDAQ:GDRX) had its target price decreased by equities research analysts at KeyCorp from $7.00 to $6.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s price target would indicate a potential upside of 40.19% from the company’s previous close.

A number of other research firms have also recently weighed in on GDRX. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Citigroup cut their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Morgan Stanley decreased their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Finally, Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.43.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $4.28 on Wednesday. GoodRx has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a market cap of $1.63 billion, a PE ratio of -142.67, a price-to-earnings-growth ratio of 3.43 and a beta of 1.27. The business’s 50 day moving average price is $4.75 and its two-hundred day moving average price is $6.59. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Hedge Funds Weigh In On GoodRx

Institutional investors have recently modified their holdings of the business. nVerses Capital LLC acquired a new stake in GoodRx in the third quarter valued at about $33,000. Plato Investment Management Ltd acquired a new stake in shares of GoodRx in the 2nd quarter valued at approximately $43,000. EP Wealth Advisors LLC bought a new stake in shares of GoodRx during the 3rd quarter valued at approximately $73,000. Dark Forest Capital Management LP acquired a new position in GoodRx during the 2nd quarter worth approximately $86,000. Finally, Sanctuary Advisors LLC bought a new position in GoodRx in the 3rd quarter valued at approximately $85,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.